Food and Drug Administration

Arthritis Advisory Committee

July 12, 2000



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Chimeric Monoclonal Antibody Against Human Tumor Necrosis Factor, Centocor Presentation  pdf

Infliximab as a Treatment for Rheumatoid Arthritis - Prevention of Structural Damage, Dr Barbara Matthews, MD, FDA  pdf

Radiographic Analyses of Disease Progression, Dr. Vibeke Strand, MD, Stanford U. School of Medicine  htm  ppt